SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has supported the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, according to a recent company announcement. The program utilizes the SSi Mantra 3.0 surgical robotic system and represents a significant step forward in advancing cardiac care in the region.
The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This collaboration underscores the company's commitment to global expansion and training local surgeons in robotic techniques.
Kings Hospital has completed more than 25 robotic procedures in just three weeks, according to a recent company video describing the program's early activity. This rapid adoption demonstrates the potential of robotic surgery to enhance surgical precision, reduce recovery times, and improve patient outcomes. The successful implementation in Sri Lanka could serve as a model for other developing healthcare markets seeking to adopt advanced surgical technologies.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, signaling a growing international presence. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These figures indicate strong demand for the SSi Mantra system and increasing adoption of robotic-assisted surgery globally.
The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open doors to the world's largest healthcare markets, potentially accelerating revenue growth and solidifying the company's position in the competitive surgical robotics industry. The successful launch in Sri Lanka adds to the company's credibility as it seeks these approvals.
For investors, the expansion into Sri Lanka and the rapid procedure adoption highlight SS Innovations' ability to penetrate new markets and drive utilization. The company's focus on cardiac surgery, a complex and high-value specialty, could differentiate it from competitors. As robotic surgery continues to gain traction worldwide, SS Innovations' progress in Sri Lanka and its regulatory pursuits will be key indicators of its long-term potential.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
